The development of Cop 1 (Copaxone®), and innovative drug for the treatment of multiple sclerosis: personal reflections
- 30 April 1996
- journal article
- review article
- Published by Elsevier in Immunology Letters
- Vol. 50 (1-2) , 1-15
- https://doi.org/10.1016/0165-2478(96)02506-0
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- On the Existence of Suppressor CellsInternational Archives of Allergy and Immunology, 1993
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987
- Chronic relapsing experimental allergic encephalomyelitis: An experimental model of multiple sclerosisAnnals of Neurology, 1977
- Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymerClinical Immunology and Immunopathology, 1974
- Sphingomyelin specific antibodies elicited by synthetic conjugatesImmunochemistry, 1973
- Correlation Between Strain Differences in Susceptibility to Experimental Allergic Encephalomyelitis and the Immune Response to Encephalitogenic Protein in Inbred Guinea PigsImmunological Communications, 1973
- Suppression of experimental allergic encephalomyelitis by chemically modified encephalitogenImmunochemistry, 1972
- Species specificity in response to tryptophan modified encephalitogenImmunochemistry, 1972
- Basic encephalitogenic protein: A simplified purification on sulphoethyl‐sephadexFEBS Letters, 1970